Jelly Roll, Mounjaro and what their story tells us about tirzepatide

What the trial evidence actually showed before the headlines started

The attention Jelly Roll brought to tirzepatide is understandable once you look at the data that preceded it. The SURMOUNT-1 trial enrolled 2,539 adults living with obesity and followed them for 72 weeks. At the highest dose, participants lost an average of around 20 to 21 percent of their body weight, figures the SURMOUNT-1 paper in the New England Journal of Medicine described as unlike anything seen in earlier weight-management medicines. That is not a modest effect. For someone starting at, say, 130 kg, a 20 percent reduction means losing around 26 kg over a year and a half of treatment.

Tirzepatide works by activating two receptors simultaneously. GIP and GLP-1 are both gut hormones involved in appetite signalling and blood-sugar control. Slowing gastric emptying, increasing the feeling of fullness after a meal, and reducing overall appetite are among the effects that have been studied. You can read more about the biological mechanisms on our tirzepatide overview page. The medicine does not melt fat through some separate process; it changes the hormonal environment that shapes hunger. A common misconception is that GLP-1 injections simply suppress willpower into submission, what the research actually suggests is that they alter appetite signalling at a physiological level, which is a different thing entirely and a more honest framing of why they can work.

None of that makes it suitable for everyone. Eligibility depends on BMI, existing health conditions, current medications and a full clinical assessment. The trial results describe an average across thousands of participants; individual outcomes vary.

How tirzepatide is licensed in the UK and who can access it

In the UK, tirzepatide is sold as Mounjaro, made by Eli Lilly, delivered as a once-weekly subcutaneous injection via a pre-filled KwikPen. Each pen contains four weekly doses. Treatment begins at 2.5 mg (a dose designed to let your body adjust gradually) and is typically increased in steps by the prescriber, with six available strengths up to 15 mg.

NICE recommends tirzepatide (TA1026, published December 2024) for adults with a BMI of 35 or above plus at least one weight-related condition such as high blood pressure, type 2 diabetes, obstructive sleep apnoea, dyslipidaemia or cardiovascular disease. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the threshold is 2.5 kg/m² lower throughout. A full description of NICE's recommendations is available on the NICE website. Private prescribing follows the SmPC, which permits treatment at a BMI of 30 or above, or 27 or above with a qualifying condition.

Jelly Roll's use of tirzepatide was reported in the US context, where the same medicine is available. UK readers should note that clinical assessment, supply and oversight here operate under UK regulation, a prescriber reviews your case before treatment begins and again before every repeat supply. The NHS route is phased and criteria are strict; private access through a regulated pharmacy is the alternative for those who do not meet NHS thresholds or prefer not to wait.

What happens to belly fat specifically, and what the evidence supports

One of the most searched questions after Jelly Roll's story broke was about visceral fat, the deeper abdominal fat linked to cardiovascular and metabolic risk. The weight lost during tirzepatide trials is not drawn from one location; the body reduces fat stores broadly. That said, visceral fat is metabolically active and tends to respond to caloric deficit, so people do often notice changes in their midsection. Our page on Mounjaro and belly fat covers what the research shows about abdominal fat reduction in more detail.

If you are curious specifically about the mechanisms involved in fat breakdown during tirzepatide treatment, the tirzepatide and lipolysis page looks at that process directly. And if you are weighing up practical questions around how long results are sustained, the tirzepatide lifespan page explores what happens after treatment ends, based on current evidence.

Side effects are worth knowing about before starting. The most commonly reported are gastrointestinal, nausea, loose stools, constipation, indigestion and reflux tend to cluster around dose increases and usually settle within a week or two. A separate concern to be aware of is acute pancreatitis: in January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines noting this as an infrequent but potentially serious effect, with severe stomach pain that may spread to the back as the warning sign requiring urgent medical attention. More on that and other side effects is on our Mounjaro abdominal discomfort page.

Starting the process in the UK

If Jelly Roll's experience prompted you to look into this properly, that is a reasonable starting point. The next step is a clinical assessment, not a purchase. For context on what private treatment typically costs in the UK (prices vary by dose and provider, and have changed since Eli Lilly adjusted list prices in September 2025) our Mounjaro price comparison page gives an honest overview of what the market looks like.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally, the same day it is submitted. There is no algorithm making the call. If you order before 12pm on a working day and the prescriber approves treatment, your medication is dispatched the same day and arrives via tracked DPD delivery the following working day, in plain packaging. Our about us page explains how the service works and how to verify our pharmacy on the GPhC register. If you have questions before starting, the FAQs page covers the ones we hear most often.

Tirzepatide is not a shortcut and it is not right for everyone. But for people who meet the clinical criteria, the evidence behind it is substantial. Check your eligibility with our prescribers if you would like to understand whether it could be appropriate for you.